Prime Medicine has cleared a clinical trial application with New Zealand’s Medsafe for PM-577a, a Prime Editor program intended for Wilson’s disease. The company’s advance moves the investigational gene-editing approach into human clinical evaluation in the jurisdiction. PM-577a is built on the Prime Editing platform, which uses an engineered system to install precise genetic changes without relying on double-strand breaks. In Wilson’s disease, where copper accumulation stems from pathogenic variants in copper metabolism pathways, targeted editing could represent a disease-modifying strategy. The clearance is a near-term milestone for the program and adds to the expanding footprint of prime-editing assets in late preclinical-to-clinic transitions.